Cargando…
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer
BACKGROUND: Murine studies suggest that myeloid cells such as vascular leukocytes (VLC) and Tie2(+ )monocytes play a critical role in tumor angiogenesis and vasculogenesis. Myeloid cells are a primary cause of resistance to anti-VEGF therapy. The elimination of these cells from the tumor microenviro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704183/ https://www.ncbi.nlm.nih.gov/pubmed/19545375 http://dx.doi.org/10.1186/1479-5876-7-49 |